Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting, 45480 [2019-18593]
Download as PDF
<![CDATA[
45480
Federal Register / Vol. 84, No. 168 / Thursday, August 29, 2019 / Notices
Season
start
State or territory
Locality
PUERTO RICO ..................................
FAJARDO [INCL ROOSEVELT RDS
NAVSTAT].
FT. BUCHANAN [INCL GSA SVC
CTR, GUAYNABO].
FT. BUCHANAN [INCL GSA SVC
CTR, GUAYNABO].
HUMACAO ........................................
LUIS MUNOZ MARIN IAP AGS .......
LUIS MUNOZ MARIN IAP AGS .......
LUQUILLO ........................................
MAYAGUEZ ......................................
PONCE .............................................
RIO GRANDE ...................................
SABANA SECA [INCL ALL MILITARY].
SABANA SECA [INCL ALL MILITARY].
SAN JUAN & NAV RES STA ...........
SAN JUAN & NAV RES STA ...........
VIEQUES ..........................................
ST. CROIX ........................................
ST. CROIX ........................................
ST. JOHN ..........................................
ST. JOHN ..........................................
ST. THOMAS ....................................
ST. THOMAS ....................................
WAKE ISLAND .................................
PUERTO RICO ..................................
PUERTO RICO ..................................
PUERTO
PUERTO
PUERTO
PUERTO
PUERTO
PUERTO
PUERTO
PUERTO
RICO
RICO
RICO
RICO
RICO
RICO
RICO
RICO
..................................
..................................
..................................
..................................
..................................
..................................
..................................
..................................
PUERTO RICO ..................................
PUERTO RICO ..................................
PUERTO RICO ..................................
PUERTO RICO ..................................
VIRGIN ISLANDS (U.S.) ...................
VIRGIN ISLANDS (U.S.) ...................
VIRGIN ISLANDS (U.S.) ...................
VIRGIN ISLANDS (U.S.) ...................
VIRGIN ISLANDS (U.S.) ...................
VIRGIN ISLANDS (U.S.) ...................
WAKE ISLAND ..................................
Season end
Lodging
Total per
diem
M&IE
Effective
date
01/01
12/31
139
92
231
10/01/2012
12/01
05/31
195
88
283
12/01/2015
06/01
11/30
167
88
255
12/01/2015
01/01
12/01
06/01
01/01
01/01
01/01
01/01
12/01
12/31
05/31
11/30
12/31
12/31
12/31
12/31
05/31
139
195
167
139
109
149
169
195
92
88
88
92
112
89
123
88
231
283
255
231
221
238
292
283
10/01/2012
12/01/2015
12/01/2015
10/01/2012
09/01/2010
09/01/2012
06/01/2012
12/01/2015
06/01
11/30
167
88
255
12/01/2015
06/01
12/01
01/01
12/15
04/15
12/04
05/01
04/15
12/16
01/01
11/30
05/31
12/31
04/14
12/14
04/30
12/03
12/15
04/14
12/31
167
195
175
299
247
230
170
249
339
129
88
88
95
116
110
113
107
110
110
70
255
283
270
415
357
343
277
359
449
199
12/01/2015
12/01/2015
03/01/2012
06/01/2015
06/01/2015
08/01/2015
08/01/2015
03/01/2017
03/01/2017
09/01/2019
* Where meals are included in the lodging rate, a traveler is only allowed a meal rate on the first and last day of travel.
[FR Doc. 2019–18690 Filed 8–28–19; 8:45 am]
BILLING CODE 5001–06–P
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary
Advisory Panel; Notice of Federal
Advisory Committee Meeting
Under Secretary of Defense for
Personnel and Readiness, Department of
Defense (DoD).
ACTION: Notice of Federal Advisory
Committee meeting.
AGENCY:
The Department of Defense
(DoD) is publishing this notice to
announce that the following Federal
Advisory Committee meeting of the
Uniform Formulary Beneficiary
Advisory Panel will take place.
DATES: Open to the public Wednesday,
September 25, 2019, from 9:00 a.m. to
12:00 p.m.
ADDRESSES: The address of the open
meeting is the Naval Heritage Center
Theater, 701 Pennsylvania Avenue NW,
Washington, DC 20004. FOR
FOR FURTHER INFORMATION CONTACT:
Colonel Paul J. Hoerner, USAF, 703–
681–2890 (Voice), dha.ncr.j6.mbx.baprequests@mail.mil (Email).
Mailing address is 7700 Arlington
Boulevard, Suite 5101, Falls Church, VA
22042–5101. Website: https://
khammond on DSKBBV9HB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:00 Aug 28, 2019
Jkt 247001
health.mil/bap. The most up-to-date
changes to the meeting agenda can be
found on the website.
SUPPLEMENTARY INFORMATION: This
meeting is being held under the
provisions of the Federal Advisory
Committee Act (FACA) of 1972 (5
U.S.C., Appendix, as amended), the
Government in the Sunshine Act of
1976 (5 U.S.C. 552b, as amended), and
41 Code of Federal Regulations (CFR)
102–3.140 and 102–3.150. The Panel
will review and comment on
recommendations made to the Director
of the Defense Health Agency, by the
Pharmacy and Therapeutics Committee,
regarding the Uniform Formulary.
Purpose of the Meeting: The DoD is
publishing this notice to announce that
the following Federal Advisory
Committee meeting of the Uniform
Formulary Beneficiary Advisory Panel
will take place.
Agenda
1. Sign-In
2. Welcome and Opening Remarks
3. Scheduled Therapeutic Class Reviews
(Comments will follow each agenda
item)
a. Multiple Sclerosis Agents—
Interferon
b. Multiple Sclerosis Agents—Methyl
Fumarate
c. Corticosteroids—Immune
Modulators—High Potency
4. Newly Approved Drugs Review
PO 00000
Frm 00018
Fmt 4703
Sfmt 4703
5. Pertinent Utilization Management
Issues
6. Panel Discussions and Vote
Meeting Accessibility: Pursuant to 5
U.S.C. 552b, as amended, and 41 CFR
102–3.140 through 102–3.165, and the
availability of space, this meeting is
open to the public. Seating is limited
and will be provided only to the first
220 people signing-in. All persons must
sign-in legibly.
Written Statements: Pursuant to 41
CFR 102–3.140, the public or interested
organizations may submit written
statements to the membership of the
Panel about its mission and/or the
agenda to be addressed in this public
meeting. Written statements should be
submitted to the Panel’s Designated
Federal Officer (DFO).The DFO’s
contact information can be obtained
previously in this notice. Written
comments or statements must be
received by the committee DFO at least
five (5) business days prior to the
meeting so that they may be made
available to the Panel for its
consideration prior to the meeting. The
DFO will review all submitted written
statements and provide copies to all the
committee members.
Dated: August 23, 2019.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison
Officer, Department of Defense.
[FR Doc. 2019–18593 Filed 8–28–19; 8:45 am]
BILLING CODE 5001–06–P
E:\FR\FM\29AUN1.SGM
29AUN1
]]>Agencies
[Federal Register Volume 84, Number 168 (Thursday, August 29, 2019)]
[Notices]
[Page 45480]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-18593]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal
Advisory Committee Meeting
AGENCY: Under Secretary of Defense for Personnel and Readiness,
Department of Defense (DoD).
ACTION: Notice of Federal Advisory Committee meeting.
-----------------------------------------------------------------------
SUMMARY: The Department of Defense (DoD) is publishing this notice to
announce that the following Federal Advisory Committee meeting of the
Uniform Formulary Beneficiary Advisory Panel will take place.
DATES: Open to the public Wednesday, September 25, 2019, from 9:00
a.m. to 12:00 p.m.
ADDRESSES: The address of the open meeting is the Naval Heritage Center
Theater, 701 Pennsylvania Avenue NW, Washington, DC 20004. FOR
FOR FURTHER INFORMATION CONTACT: Colonel Paul J. Hoerner, USAF, 703-
681-2890 (Voice), [email protected] (Email). Mailing
address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA
22042-5101. Website: https://health.mil/bap. The most up-to-date
changes to the meeting agenda can be found on the website.
SUPPLEMENTARY INFORMATION: This meeting is being held under the
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5
U.S.C., Appendix, as amended), the Government in the Sunshine Act of
1976 (5 U.S.C. 552b, as amended), and 41 Code of Federal Regulations
(CFR) 102-3.140 and 102-3.150. The Panel will review and comment on
recommendations made to the Director of the Defense Health Agency, by
the Pharmacy and Therapeutics Committee, regarding the Uniform
Formulary.
Purpose of the Meeting: The DoD is publishing this notice to
announce that the following Federal Advisory Committee meeting of the
Uniform Formulary Beneficiary Advisory Panel will take place.
Agenda
1. Sign-In
2. Welcome and Opening Remarks
3. Scheduled Therapeutic Class Reviews (Comments will follow each
agenda item)
a. Multiple Sclerosis Agents--Interferon
b. Multiple Sclerosis Agents--Methyl Fumarate
c. Corticosteroids--Immune Modulators--High Potency
4. Newly Approved Drugs Review
5. Pertinent Utilization Management Issues
6. Panel Discussions and Vote
Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and
41 CFR 102-3.140 through 102-3.165, and the availability of space, this
meeting is open to the public. Seating is limited and will be provided
only to the first 220 people signing-in. All persons must sign-in
legibly.
Written Statements: Pursuant to 41 CFR 102-3.140, the public or
interested organizations may submit written statements to the
membership of the Panel about its mission and/or the agenda to be
addressed in this public meeting. Written statements should be
submitted to the Panel's Designated Federal Officer (DFO).The DFO's
contact information can be obtained previously in this notice. Written
comments or statements must be received by the committee DFO at least
five (5) business days prior to the meeting so that they may be made
available to the Panel for its consideration prior to the meeting. The
DFO will review all submitted written statements and provide copies to
all the committee members.
Dated: August 23, 2019.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2019-18593 Filed 8-28-19; 8:45 am]
BILLING CODE 5001-06-P
